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Abstract
Background: Drugs predominantly prescribed in general practice should ideally be tested in that setting; however,
little is known about drug trials in general practice. Our aim was to describe drug trials in Norwegian general
practice over the period of a decade.
Methods: The present work concerns a 10-year retrospective study of protocols submitted to the Norwegian
national medicines agency (1998 to 2007) identifying all studies involving general practitioners (GPs) as clinical
investigator(s). We analyzed the number of trials, drug company involvement, patients, participating doctors,
payment, medications tested and main diagnostic criteria for inclusion. We also analyzed one trial in greater detail.
Results: Out of 2,054 clinical drug trials, 196 (9.5%) were undertaken in general practice; 93% were multinational,
96% were industry funded and 77% included patients both from general practice and specialist care. The trials were
planned to be completed in the period 1998 to 2012. A total of 23,000 patients in Norway and 340,000 patients
internationally were planned to be included in the 196 trials. A median of 5 GPs participated in each trial (range 1
to 402). Only 0.7% of 831 GP investigators had general practice university affiliations. Median payment for
participating investigators was €1,900 (range €0 to 13,500) per patient completing the trial. A total of 30
pharmaceutical companies were involved. The drugs most commonly studied were antidiabetics (21%), obstructive
airway disease medications (12%), agents acting on the renin-angiotensin system (10%), and lipid modifying agents
(10%). One trial, presented in more detail, had several characteristics of a seeding or marketing trial.
Conclusions: Only one in four drug trials involving general practice were solely general practice trials and almost
all were industry initiated without input from academic general practice. There was a large variation in the number
of patients, participating doctors, and economic compensation for trial investigators, with some investigators
receiving substantial payments.
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Background
About 90% of all drug prescriptions for outpatients are
issued in general practice [1]. Patients in general practice
are more likely to have less severe disease, and more un-
differentiated symptoms than selected patients in sec-
ondary or tertiary health care, however, multimorbidity
is common [2]. If a study population in a drug trial dif-
fers significantly from the population where the drug is
most likely to be prescribed, the external validity of the
trial may be impaired [3]. To avoid this uncertainty,
many have argued that more clinical drug trials should
be conducted in primary care settings to ensure that the
benefits are proportionate to the risks and costs of the
treatment for patients in general practice [4,5]. Clinical
drug trials may serve different purposes, from research
of effectiveness, to marketing [6]. Trials with the main
purpose of introducing new drugs to prescribers are
often referred to as ‘seeding trials’. Various criteria for
seeding trials have been proposed (Table 1) [7-9], and it
is characteristic that the trials are designed to make
many clinicians familiar with a new drug. Being frequent
prescribers, general practitioners (GPs) are probably of
particular interest for designers of seeding trials; this is
also because GPs are relatively independent in their
decision-making processes.
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In the UK between 1984 and 1989, general practice tri-
als initiated by pharmaceutical companies were judged
to have a low output of clinically relevant results [10].
The concerns addressed in that audit were mainly pay-
ments to GPs, information and safety issues, shortfall of
investigators and patients, leading to inconclusive re-
sults, and low publication rates [10]. Among general
practice studies published 1991 to 1996 in the BMJ, the
British Journal of General Practice, and Family Practice,
only 6% were randomized controlled trials, which was
pointed out as a major challenge for the general practice
research community [11]. Some Norwegian data regard-
ing clinical drug trials have previously been reported,
based on research applications submitted to the Re-
search Ethical Committees (REC) [12-14] and the
Norwegian Medicines Agency (NoMA) [15,16]. Between
68% and 85% of the trials were initiated by pharmaceut-
ical industry [13-15], however, neither of these reports
highlighted studies in general practice.
From the 1970s, a subcommittee of the Norwegian
College of General Practitioners had a voluntary agree-
ment with the pharmaceutical industry to assess proto-
cols for studies to be performed in general practice
[17,18]. If the committee judged the trial to be clinically
relevant and of sound scientific quality, GPs were
recommended to participate in the trial. However, by the
turn of the millennium, the committee voiced critical
comments regarding some trials judged to be marketing
(due to features of seeding trials) rather than research
[17]. Since then, this voluntary quality and relevance
check has been largely bypassed by the industry [19],
and information regarding industry initiated research in
Norwegian general practice has thus become an almost
hidden reality except for the investigators themselves.
This prompted the Norwegian College of General Practi-
tioners in 2008 to fund research to gain systematic
knowledge of the drug research carried out by GPs. This
included establishing an overview of all trials conducted,
exploring whether GPs were subject for marketing trials,
and assessing the relevance of the research questions
addressed, as well as the studies’ validity and publication
output. The College requested this knowledge due to
possible implications for their policy for future profes-
sional development within the discipline of general
practice.
The aim of the present study was to establish a de-
scriptive basis regarding clinical drug trials conducted in
general practice by research areas and trial characteris-
tics. As most clinical drug trials are multinational, this
study also should concern research in general practice
outside of Norway.
Methods
In Norway, the only complete national archive for drug
trials is held by NoMA. Based on a hand search of the
NoMA archive for the 10-year period 1998 to 2007, we
describe all clinical trials planned to be carried out in
general practice by their funding, clinical setting, drugs,
diagnoses, patients, clinical investigators and economic
compensations for the investigators. More detail will be
given regarding one of the trials in year 2000, which the
Norwegian College of GPs discouraged GPs to join [17],
to give the reader a better sense of what we consider a
seeding trial. Ethical approval for our study was not
required.
Dataset
In Norway, all clinical pharmaceutical trials regardless of
setting need approval from NoMA, the national, regula-
tory authority for new and existing medicines. Clinical tri-
als are regulated by international and national laws, in
which there were amendments between 1998 and 2007,
and from 2004 the European Directive 2001/20/EC has
been implemented in the Norwegian regulation [16]. By
Table 1 Case study: the ‘On-demand Nexium Evaluation’ (ONE) triala
Key characteristics of seeding trials [7-9] Does this apply for the ONE trial?
Tests a new drug recently or about to be licensed Yes: application year 2000, study completed by the end of 2001; esomeprazole licensed in 2001
Many well established competing products Yes: omeprazole from 1989, lansoprazole and pantoprazole from 1995
Many patients included Yes: 2,500 patients (the trial with most Norwegian patients to be included). In addition, similar
studies have been conducted in other countries (see main text).
Frequent prescribers in the role of clinical
investigators
Yes: 402 general practitioners (GPs; the study involving most Norwegian GP investigators)
Often redundant as they are not designed for
answering a scientific problem
Probably yes
Unreasonably high payments for the investigators No: €750 which is below the 25th percentile for all trials
Results are often not published No: there were three publications
Conducted by drug company marketing departments Unknown
aFull trial title: ‘Long-term treatment of patients with symptomatic gastroesophageal reflux disease (GERD) comparing costs and efficacy over six months of
treatment with esomeprazole 20 mg q.d on demand treatment or esomeprazole 20 mg q.d continuous treatment or ranitidine 150 mg b.i.d. continuous
treatment. An open, randomised, multicenter study. On-demand Nexium Evaluation - ONE’. Sponsor: AstraZeneca.
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hand searching NoMA’s total paper archive, protocol by
protocol, we were able to identify application forms, pro-
tocols and other correspondence received by NoMA re-
garding applications for clinical drug trials between 1998
and 2007, the 10-year period before conversion to elec-
tronic registration. The computed total number of trial ap-
plications during this decade was 2,054 [16,20] (personal
communication from I. Aaløkken, NoMA). The main
hand search was performed in May to August 2008 by
KBJ. Supplementary data collection and verification was
performed by AMB between November to December
2011 for a total of 89 studies. No formal inter-rater reli-
ability calculations were performed, but no significant er-
rors or discrepancies were disclosed. A random check of
non-included studies in the archive did not reveal any
additional general practice trials. Applications for trials
planned to take place solely or partly in general practice
were included. General practice trials were defined as tri-
als where the address and/or titles indicated that at least
one of the Norwegian clinical investigators worked in gen-
eral practice.
Variables: trial characteristics
For included studies, we recorded study title, medication
tested in terms of its Anatomical Therapeutic Chemical
(ATC) classification code [21], funders, whether the
study was planned exclusively to be conducted in gen-
eral practice or also in specialist care settings, whether it
was a national or international study, and trial phase
based on explicit information in the application ((I)
study of toxicity and side effects; (II) study of dose-
response; (III) comparison with established treatment or
placebo; or (IV) post-marketing study, gaining broader
experience) [6]. We defined a study as industry initiated
when a pharmaceutical company funded the study, wrote
the study protocol or conducted the study, either the com-
pany itself or via a contract research organization. If the
study drugs were provided free of charge, but the trial was
otherwise designed and conducted independently under
the responsibility of a GP researcher, it was defined as re-
searcher initiated. There were no trials with unclear
funding. We recorded the number of patients planned to
be included internationally, and at Norwegian trial sites, the
number of clinical investigators involved, trial duration, and
if available, economic compensation for physicians in-
volved. We also identified clinical investigators who were
GP academics, that is, having affiliations to Norwegian gen-
eral practice university departments. The main diagnostic
criteria for inclusion in a study were based on the study
title, and when necessary supplemented with information
from the protocol and categorized according to the
International Classification of Primary Care, second
edition (ICPC-2) [22]. One of the authors (AMB)
performed the categorization, and when in doubt,
consensus was reached through discussions between
AK, JS and AMB.
Data analysis
Data were compiled in a spreadsheet. To compare
planned number of patients to be enrolled in trials partly
or entirely to be undertaken in general practice, we used
the independent samples Mann-Whitney U test, and
otherwise we used descriptive statistics. Due to data
skewness, median values are presented rather than
means. We roughly estimated investigator incomes by
multiplying median payment and median number of pa-
tients planned recruited divided by median number of
investigators. Statistical analyses were performed using
SPSS statistics (PASW Statistics 18; SPSS Inc., Chicago,
IL, USA).
Case study
One outlying case is described in greater detail. For this
trial, additional information is given on patients, inter-
ventions, comparison and outcome based on the study
protocol. A systematic literature search was performed
to identify publications arising from the trial (date of lit-
erature search, 17 September 2012). The trial was
assessed according to the proposed criteria for seeding
trials outlined in Table 1 [7-9].
Results
Dataset: general practice drug trials
During the 10-year period of applications, a total of 196
studies (9.5% of all 2,054 clinical drug trials) were planned
to be conducted entirely or partly in a general practice set-
ting. Of these, 189 (96.4%) trials were industry initiated
and 7 (3.6%) were researcher initiated (Table 2). The trials
were planned to be completed in the period 1998 to 2012.
Figure 1 shows that the majority of the 196 trials had trial
sites both in general practice and in specialist care. The
majority of the trials were multinational. Only 45 trials
(2.2% of all) were planned conducted entirely in general
practice. The number of participating countries per trial
varied from 1 to 50 (median: 9, interquartile range 5 to
17); however, for 112 trials information regarding the
number of countries was incompletely stated.
Trial characteristics
A total of 30 different pharmaceutical companies applied
for drug trials in general practice during this 10-year
period. The initiators (number of trials) were Glaxo-
SmithKline (39), AstraZeneca (32), Novartis (21), MSD
(19), Pfizer (11), Novo Nordisk (9), Boehringer Ingelheim
(8), Roche (7), Lundbeck (5), and Schering-Plough (4). In
addition, 5 companies initiated 3 trials, 4 companies ini-
tiated 2 trials, and 11 companies initiated 1 trial. The top
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5 companies in terms of Norwegian market share [23]
were responsible for 107 (55%) of all trials.
Table 3 shows the number of patients and physicians in-
volved and estimated economic compensation for the in-
vestigators. More than 23,000 Norwegian patients were to
be included in the 196 trials, and almost 340,000 patients
included internationally. In 6 trials the planned number of
included patients was more than 10,000, and in 10 trials the
number was less than 100 patients. The recruitment targets
did not differ between trials in general practice only and
those undertaken in mixed health care settings (P = 0.91).
Only 6 (0.7%) out of 831 clinical investigators were general
practice academics, 3 of whom were only involved in trials
without commercial sponsors. Information regarding trial
investigators’ payment was missing in 90 applications, 73 of
which were from the period 1998 to 2002.
We were able to record the study phase in 122 trials, out
of which none were phase I studies, 11% were phase II
studies, 61% phase III and 27% phase IV studies.
Drugs from 30 different therapeutic groups were in-
vestigated in the trials (Table 4). The largest groups were
antidiabetics, drugs for obstructive airway diseases,
agents acting on the renin-angiotensin system, and lipid
modifying agents. The top 5 therapeutic subgroups rep-
resented 121 (59%) of all drug groups tested, the top 10
represented 158 (78%). Only one of the trials investi-
gated medication discontinuation.
The main diagnostic inclusion criteria represented 44
different diagnoses (Table 5), the top 5 of which made
up 114 (52% of the inclusion criteria) and the top 10
made up 146 (67%). In 14 trials no diagnosis was applic-
able, that is, healthy people, subjects over a certain age,
smokers, and patients using baby aspirin.
Case study
In Table 1, more detail is given for one particular trial
which the Norwegian College of GPs discouraged GPs to
Table 2 Clinical drug trial applications in Norway 1998 to 2007
Year General practice trials All clinical trials
Industry initiated (GP only) Researcher initiateda Total (GP only) Industry initiated Researcher initiated Total
1998 17 (7) 0 17 (7) 186 50 236b
1999 16 (6) 0 16 (6) 161 28 189c
2000 23 (10) 1 24 (11) 173 65 238d
2001 22 (1) 0 22 (1) 158 62 220d
2002 16 (5) 2 18 (7) 143 50 193d
2003 14 (1) 1 15 (2) 151 50 201d
2004 22 (2) 1 23 (3) 171 60 231d
2005 18 (2) 1 19 (3) 139 55 194d
2006 20 (1) 1 21 (2) 113 60 173d
2007 21 (3) 0 21 (3) 126 53 179d
Total 189 (38) 7 196 (45) 1,521 533 2,054
Mean/year 18.9 (3.8) 0.7 19.6 (4.5) 152.1 53.3 205.4
Applications at the Norwegian Medicines Agency (NoMA) for clinical drug trials conducted entirely (general practitioners (GPs) only) or partly in general practice
identified by hand searching of all the clinical trials in the archive. For comparison, an overview of all clinical trials is included.
aAll researcher-initiated trials were GP only.
bPersonal communication from Ingvild Aaløkken, Head of section, Preclinical assessment and clinical trials, NoMA, 2008.
cSee [16].
dSee [20].
Figure 1 General practice clinical drug trials in Norway 1998 to
2007. Applications to the Norwegian Medicines Agency (NoMA) for
industry initiated or researcher initiated clinical drug trials conducted
entirely or partly in general practice as identified by hand search of
the clinical trials archive. A total number of 2,054 clinical drug trials
during the time period was calculated (personal communication
from Ingvild Aaløkken, Head of section, Preclinical assessment and
clinical trials, NoMA, 2008; see also [16,20]).
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join [17], the ‘On-demand Nexium Evaluation’ trial,
with the following clinical characteristics. Patients: pa-
tients with symptoms suggestive of gastroesophageal re-
flux disease (GERD; heartburn with or without acid
regurgitation) for 3 days or more were included. Only
patients with effect of treatment with esomeprazole 40
mg were randomized for comparison with ranitidine.
Intervention: the drug tested was esomeprazole 40/20
mg daily. Comparison: there was initially no com-
parison; if treatment success in the run-in period with
esomeprazole 40 mg daily, comparison was esome-
prazole 20 mg daily on demand or ranitidine 150 mg
twice daily. Outcomes: difference in direct medical
costs (mean per patient) was the primary outcome, sec-
ondary objectives included health care contacts, tests
and procedures, hospitalizations, patient time and travel
costs, early retirement, absence from work, symptom
registration, quality of life, self-perceived overall treat-
ment effect, and patient satisfaction. Among all 196 tri-
als in Norwegian general practice during the decade,
this trial was designed to include the largest number of
national GP investigators and patients. In the sample
size calculations a power of 95% (beta = 0.05) was used.
The significance level alpha was 5%. The study had an
open design, with no blinding. There was a run-in period
before randomization, and only patients responding to the
high dose esomeprazole treatment were randomized and
included in the intention-to-treat analyses. Per protocol
analyses were also used. Three journal articles presenting
results from the study were identified [24-26].
Discussion
The main findings in this study were that only about one-
tenth of all clinical drug trials in Norway involved GPs as
clinical investigators recruiting patients from their prac-
tices, and only 3.6% of these were non-industry trials.
We found that the proportion of researcher-initiated
clinical drug trials in general practice in Norway was
minute (3.6%) compared to clinical drug trials from
other fields of medicine where 15% to 32% are non-
commercial studies [13-15]. Conducting clinical trials in
general practice poses some typical challenges, like diffi-
culties with study logistics and patient recruitment in a
large number of small trial sites [4]. The lack of
researcher-initiated trials has also been pointed out in
the European Research Agenda for General Practice [5].
Irrespective of their commercial interests, this research
agenda underlines that drugs mainly targeting primary
care should be appropriately tested in primary care set-
tings. Furthermore, that a stable funding and formation
of research networks may facilitate non-commercial ran-
domized controlled trials in general practice [5]. Al-
though many have pointed to the need for clinical drug
trials conducted independently of the industry, there was
nonetheless a decline in the number of non-commercial
randomized controlled trials in the UK between 1980
and 2002 [27]. Several systematic reviews have pointed
out that drug trials financed by pharmaceutical industry
tend to publish results more in favor of the manufac-
turer’s product than non-commercial trials, and that
negative studies in this respect commonly remain un-
published [28-32]. This publication bias combined with
the lack of non-industry trials in general practice might
therefore contribute to an evidence-biased knowledge
base.
Over the last few years, there has been a decline in the
number of clinical trials in several European countries
[33,34]. In Norway, the largest reduction has been in
phase III studies [16]. For general practice studies we
were not able to confirm this trend, even if the majority
of trials in our material were phase III or IV. The trials
where explicit information regarding trial phase was
missing, were most likely also phase III or IV. The five
companies funding most general practice trials were
among the seven most profitable companies, thus largely
reflecting their market positions [23].
Table 3 Characteristics for clinical drug trials in general practice
Patients planned for inclusion Clinical investigators Payment
Norway All
countries
Trial duration,
weeks
General
practicea
All sites in
Norway
Investigators' payment per
patient, €b
Estimated yearly income per
investigator, €c
Median 60 672.5 24 5 7 1,900 1,600
Minimum to
maximum
8 to 2,500 8 to 31,000 1 to 288 1 to 402 1 to 402 0 to 13,500 0 to 59,000
2.5 to 97.5
percentile
13 to 560 50 to 14,368 3 to 240 1 to 37 1 to 61 0 to 7,500 0 to 25,000
Sum 23,635 337,921 1,920 2,475
This table shows trial characteristics of applications at the Norwegian Medicines Agency (NoMA), 1998 to 2007, for 196 clinical drug trials conducted solely or
partly in general practice identified by hand searching of the archive.
aGeneral practitioners (GPs) participated in clinical trials from 1 to 36 times, with median 1 and interquartile range 1 to 2. A total of 831 unique GPs participated.
bInformation missing in 90 applications.
cCalculated using median payment and median number of patients recruited per investigator. This payment covers all expenses connected with the trial for
the investigator.
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A study from 2000 found that 84% of GPs in a part of
England had been involved in research, 48% mainly in clin-
ical trials [35]. Our figures indicate that Norwegian GPs’
participation rate in clinical trials is less than half of that in
the UK; the 831 GPs involved correspond to about 20% of
all Norwegian GPs in 2002 [1]. Surprisingly few GPs with
university affiliations had participated in clinical drug trials,
although many of them work part-time as GPs and are par-
ticularly interested in clinical research. Explanations for this
finding may be that they judged the clinical relevance of
the industry funded trials to be low, feared conflicts of
interest, or had general negative attitudes towards collabor-
ation with pharmaceutical companies [36]. Most GPs in-
volved in clinical trials only participated once or just a few
times, and did therefore not gain large incomes for partici-
pating. However, a number of GPs were involved in quite a
few trials, giving them a substantial yearly income from trial
participation. A few trials also gave outstandingly high
Table 4 Anatomical Therapeutic Chemical classification (ATC codea) for test drugs in clinical drug trials in general
practice
Anatomical main ATC group n % Therapeutic ATC subgroup n % Rank (1 to 10)
A: Alimentary tract and metabolism 52 25.5 A02: Drugs for acid-related disordersb 7 3.4 7
A03: Drugs for functional gastrointestinal disorders 2 1.0
A08: Antiobesity preparations, excluding diet products 1 0.5
A10: Drugs used in diabetesb 42 20.6 1
B: Blood and blood-forming organs 4 2.0 B01: Antithrombotic agents 4 2.0
C: Cardiovascular system 46 22.5 C02: Antihypertensives 2 1.0
C08: Calcium channel blockersb 2 1.0
C09: Agents acting on the renin-angiotensin system 21 10.3 3
C10: Lipid modifying agentsb 21 10.3 3
D: Dermatologicals 2 1.0 D01: Antifungals for dermatological use 1 0.5
D04: Antipruritics, including antihistamines, anesthetics, etc. 1 0.5
G: Genitourinary system and sex hormones 8 3.9 G02: Other gynecologicals 1 0.5
G03: Sex hormones and modulators of the genital system 2 1.0
G04: Urologicals 5 2.5 10
H: Systemic hormonal preparations 3 1.5 H02: Corticosteroids for systemic usec 2 1.0
H05: Calcium homeostasis 1 0.5
J: Anti-infectives for systemic use 22 10.8 J01: Antibacterials for systemic useb 4 2.0
J05: Antivirals for systemic use 12 5.9 6
J07: Vaccines 6 2.9 9
L: Antineoplastic and immunomodulating agents 2 1.0 L01: Antineoplastic agents 2 1.0
M: Musculoskeletal system 15 7.4 M01: Anti-inflammatory and antirheumatic products 13 6.4 5
M05: Drugs for treatment of bone diseases 2 1.0
N: Nervous system 23 11.3 N02: Analgesics 7 3.4 7
N04: Anti-Parkinson drugs 2 1.0
N05: Psycholepticsc 5 2.5
N06: Psychoanalepticsc 5 2.5
N07: Other nervous system drugs 4 2.0
R: Respiratory system 26 12.7 R01: Nasal preparations 1 0.5
R03: Drugs for obstructive airway diseasesc 24 11.8 2
R06: Antihistamines for systemic use 1 0.5
Missing information 1 0.5
Total number of ATC codes 204 100
This table shows the ATC codes of drug being tested identified from applications to the Norwegian Medicines Agency (NoMA) for 196 clinical drug trials between
1998 and 2007 conducted entirely or partly in general practice through hand searching the archive.
aSee [21].
bAdditional ATC code in a total of eight trials with two ATC codes registered.
cATC code in researcher-initiated trials; for the groups H02, N05 and R03 there were two trials.
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payment for the doctors involved. Most GPs in Norway are
self-employed with a major part of their income from
patient payment and per capita reimbursement. It is there-
fore reasonable that extra workload due to participation in
clinical trials is compensated. But how much is a reasonable
level of compensation? Payment to clinicians for participa-
tion in clinical trials varies a lot [36,37]. Andersen et al.
report payments of US $800 per patient enrolled for a
Danish industry initiated trial [37], which is approximately
one-third of the median payment in our material. Raftery et
al. point to the striking lack of transparency in guidelines
for payments for involvement in research, where GPs are
among the few individual clinicians where direct personal
payment still is common [36]. Concerns have been voiced
that high payments may create conflicts of interest and
possibly lead to unethical recruitment processes [36]. This
demands rigorous ethical standards from both the general
practice community and the pharmaceutical industry.
We identified antidiabetic drugs and type II diabetes to
be studied most frequently. Thomas et al. found few
published articles on diabetes in UK primary care journals
in the 1990s [11]. The general use of antidiabetics in
Norway increased by 27% (in defined daily doses (DDDs))
from 2004 to 2008 [38]. This may both reflect increasing
diabetes prevalence but also the introduction of new drugs.
Andersen et al. found that physicians conducting a clinical
trial, significantly increased the sponsor’s share of pre-
scribed drugs for the disease compared to GPs not
involved in the trials [37], and this might be important for
expanding the market. The many post-marketing studies
of new and expensive insulin analogues with large market
potentials have recently been criticized for limited
scientific value [9]. The three largest drug groups investi-
gated in our study were among the four most consumed
drugs in Norway (in terms of DDDs) [38]. These thera-
peutic areas were also among the six most frequently
researched topics in general practice internationally
Table 5 Main diagnostic criteria for inclusion classified in
terms of International Classification of Primary Care (ICPC)
diagnosesa for clinical drug trials
ICPC diagnosis n % GP
only
T90: Diabetes, non-insulin dependent 44 20.2 1
K86: Hypertension, uncomplicated 22 10.1 7
R96: Asthma 19 8.7 4
T93: Lipid disorder 18 8.3 2
R80: Influenza 11 5.0 7
L89: Osteoarthrosis of hip 7 3.2 2
L90: Osteoarthrosis of knee 7 3.2 3
N89: Migraine 7 3.2 1
R95: Chronic obstructive pulmonary disease 6 2.8 2
P76: Depressive disorder 5 2.3 2
K78: Atrial fibrillation/flutter 4 1.8
L88: Rheumatoid/seropositive arthritis 4 1.8
T82: Obesity 4 1.8
D07: Dyspepsia/indigestion 3 1.4 2
P70: Dementia 3 1.4 2
T99: Endocrine/metabolic/nutritional disease, other 3 1.4
D84: Oesophagus disease 2 0.9 2
D93: Irritable bowel syndrome 2 0.9 1
L84: Back syndrome without radiating pain 2 0.9 1
L91: Osteoarthrosis, other 2 0.9 1
L95: Osteoporosis 2 0.9
N04: Restless legs 2 0.9
P06: Sleep disturbance 2 0.9
R78: Acute bronchitis/bronchiolitis 2 0.9 2
U04: Incontinence, urine 2 0.9
Y07: Impotence, not otherwise specified 2 0.9
A23: Risk factor, not otherwise specified 1 0.5 1
A91: Abnormal result investigation, not otherwise
specified
1 0.5
D12: Constipation 1 0.5
K76: Ischemic heart disease without angina 1 0.5
K99: Cardiovascular disease, other 1 0.5
L29: Symptom/complaint, musculoskeletal, other 1 0.5
L92: Shoulder syndrome 1 0.5 1
L93: Tennis elbow 1 0.5 1
L99: Musculoskeletal disease, other 1 0.5
R28: Limited function/disability (respiratory) 1 0.5
R75: Sinusitis, acute/chronic 1 0.5 1
R76: Tonsillitis, acute 1 0.5 1
R81: Pneumonia 1 0.5
R97: Allergic rhinitis 1 0.5
Table 5 Main diagnostic criteria for inclusion classified in
terms of International Classification of Primary Care (ICPC)
diagnosesa for clinical drug trials (Continued)
S74: Dermatophytosis 1 0.5 1
T89: Diabetes, insulin dependent 1 0.5
X11: Menopausal symptom/complaint 1 0.5
No diagnosis applicable 14 6.4 2
Totalb 218 100
Table shows main inclusion criteria classified as ICPC diagnoses identified from
applications at the Norwegian Medicines Agency (NoMA) for 196 clinical drug
trials between 1998 to 2007 conducted entirely (general practitioner (GP) only)
or partly in general practice through hand searching of the archive.
aSee [22].
bA total of 22 studies had 2 or more diagnoses as inclusion criteria; 3 studies
had 3 diagnoses.
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between 2003 and 2008 [5]. In Norway in years 2000 and
2004 [14], and in the UK 1980 to 2002 [27], most clinical
trials were in the field of cancer and antineoplastic and
immunomodulating drugs. We only identified two trials in
this field. This was as expected, as GPs rarely initiate anti-
neoplastic drug prescriptions. Only one trial studied the ef-
fects of discontinuation of (unnecessary) medication use,
although this is an important topic both for quality of care
and general practice research [5].
Strengths and limitations of the study
The NoMA archive is a mandatory, complete national
archive of all clinical drug trials in Norway, and it is a
strength that we managed to include all trial protocols,
not restricted to a specific region or to trials that had
been reported in scientific publications. The large pro-
portion of multinational trials identified also increases
the external validity of our findings, which therefore
may be relevant for general practice in other countries.
As the identification of trials was performed by hand
searching, random errors may have occurred during this
process and recording of results. The main hand search
was performed by only one of the authors, but supple-
mentary searches in the archive for completing informa-
tion by another author did not reveal significant errors.
The total number of trials (2,054 trials) for the 10-year
period was summed up from numbers provided by
NoMA, and the exact total number of investigated paper
files was not recorded, although the whole archive was
searched shelf by shelf. Some uncertainty regarding
missing files in the archive is therefore possible, how-
ever, we believe the number of missing files to be negli-
gible due to strict control and restricted access to the
state run archive. We have not addressed the number of
clinical trials that were never conducted, either from
lack of approval from REC or NoMA, or for other rea-
sons, but this will be a subject of future research. The
patient numbers reported involve all trial sites in
Norway, and we do not know the exact number of gen-
eral practice patients. Concerning trial phase, the pro-
portion of missing data was quite large. The same
applies to investigator payments, which were under-
reported to NoMA, especially during the first years in
the time period studied.
Case study: a seeding trial?
The intentions for conducting a seeding trial are in gen-
eral hidden and they may therefore be difficult to iden-
tify. Seeding trials have usually been disclosed based on
documents from litigation processes [39,40]. Without
access to internal communication within the drug com-
pany, the judgment of whether a trial is designed for
marketing has to be based on several aspects. The eso-
meprazole trial described has many features being
typical for a seeding trial, with several of the key chara-
cteristics described in Table 1 [7-9].
Esomeprazole was launched in 2001 in a crowded drug
group. It is the most expensive of the proton pump in-
hibitors, and had become the tenth most-sold medicine
in Norway in 2008 calculated in terms of pharmacy retail
prices [38]. The esomeprazole trial described was large,
and the sample size calculations were based on a higher
power than conventionally used [41]. A higher power
demands larger sample sizes and more patients to be en-
rolled into the study. No ethical considerations regarding
these issues were discussed in the peer-reviewed publica-
tions arising from the trial [24-26]. The open design and
the inclusion only of patients responding to high doses
of esomeprazole in the intention-to-treat analyses in-
creased the risk of bias in favor of esomeprazole. One
may question the scientific need for recruiting around
400 GPs in the trial, each GP only enrolling a handful of
patients with gastroesophageal reflux, a relatively com-
mon health complaint. The large number of participat-
ing doctors was not explained or justified in the protocol
or in publications arising from the trial [24-26]. Never-
theless, the trial was approved by both the regional eth-
ics committee and NoMA without any major remarks.
The general practice research committee criticized this
protocol on several issues, some of which are listed
above [17,19,42]. The trial was presented in Norway as a
separate trial, but quite similar studies with the same
protocol acronym (ONE) have been reported from
Denmark (without ranitidine comparison) [43] and
Switzerland [44] in total involving almost 3,500 patients.
Conclusions
Only one-tenth of all clinical drug trials in Norway in-
volved patients recruited from general practice, and just
one in four of these trials were solely general practice tri-
als. Almost all trials were industry initiated without input
from academic general practice. This shows that it is a
challenge for general practice to increase the number of
clinical trials in general and researcher initiated clinical
drug trials in particular. Antidiabetic drugs were most
commonly studied. There was a large variation in the
number of patients, participating doctors, and economic
compensation for trial investigators, with some investiga-
tors receiving substantial payments. We describe a study
with several characteristics of a seeding trial, where none
of the official approving bodies for clinical trials had any
major remarks. It raises the important ethical consider-
ations with regard to exposing patients to unnecessary
risks in either an inordinately large or a small, underpow-
ered trial.
In this descriptive study, we have addressed neither the
relevance of the research questions for general practice
nor the methodological quality or publication output of
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the trials beyond the case study. These are important is-
sues that we intend to explore in forthcoming research.
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